News from Bayer
June 23, 2022
Vividion Therapeutics names Aleksandra Rizo as President and Head of Research and Development
June 21, 2022
Not intended for U.S. and UK Media
Rivaroxaban (Xarelto™) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation
June 09, 2022
Bayer’s Vividion emerging as significant player in San Diego biotech hub